# Phase 3 Depressive Disorder trials recruiting: 41 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 41 trials in phase 3 for Depressive Disorder that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 Depressive Disorder trials: 41 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/depressive-disorder

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 41
- Recruiting or not yet: 41
- Read on: November 19, 2026

## Trials

The 25 newest of 41, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 28, 2026 | NCT07843927 | Dehydroepiandrosterone (DHEA) as Augmentation of Standard Antidepressants in Treatment-resistant Depression. | Charite University, Berlin, Germany | Phase 3 | Recruiting | Treatment Resistant Depression (TRD) | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843927) |
| August 24, 2026 | NCT07781293 | Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant... | Bukwang Pharmaceutical | Phase 3 | Not yet recruiting | Major Depressive Disorder (MDD), Major Depressive Disorder With Psychotic Features | 364 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781293) |
| August 20, 2026 | NCT07775300 | A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder | Eli Lilly and Company | Phase 3 | Recruiting | Depressive Disorder, Major | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07775300) |
| August 12, 2026 | NCT07760168 | Study of rTMS in Maintenance in Treatment Resistant Depression | All India Institute of Medical Sciences, Bhubaneswar | Phase 3 | Not yet recruiting | Treatment Resistant Depression (TRD) | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760168) |
| August 5, 2026 | NCT07747389 | A Study of Lumateperone Versus Placebo in Participants With Major Depressive Disorder | Intra-Cellular Therapies, Inc. | Phase 3 | Not yet recruiting | Depressive Disorder, Major | 585 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07747389) |
| August 3, 2026 | NCT07741331 | Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive Disorder | Chengdu Kanghong Pharmaceutical Group Co., Ltd. | Phase 3 | Not yet recruiting | Major Depressive Disorder (MDD) | 326 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07741331) |
| August 3, 2026 | NCT07741240 | A Study of KH607 as Monotherpy in Adults Participants With Major Depressive Disorder | Chengdu Kanghong Pharmaceutical Group Co., Ltd. | Phase 3 | Not yet recruiting | Major Depressive Disorder (MDD) | 232 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07741240) |
| July 21, 2026 | NCT07716098 | A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression | Janssen Research & Development, LLC | Phase 3 | Recruiting | Depressive Disorder, Treatment-Resistant | 348 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07716098) |
| July 14, 2026 | NCT07703722 | Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder | Khyber Medical University Peshawar | Phase 3 | Recruiting | Major Depressive Disorder, Post-Traumatic Stress Disorder (PTSD) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07703722) |
| June 3, 2026 | NCT07623135 | Lumateperone for Late-Life Depression | Sponsor not shown (see the record) | Phase 3 | Recruiting | Treatment Resistant Depression (TRD), Late Life Depression (LLD), Depression / Major Depressive Disorder | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623135) |
| May 18, 2026 | NCT07592689 | A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) | Definium Therapeutics US, Inc. | Phase 3 | Recruiting | Major Depressive Disorder | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07592689) |
| May 7, 2026 | NCT07573176 | A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder | Janssen Research & Development, LLC | Phase 3 | Recruiting | Depressive Disorder, Major | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07573176) |
| March 20, 2026 | NCT07484217 | Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol | Axsome Therapeutics, Inc. | Phase 3 | Recruiting | Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | 508 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07484217) |
| February 17, 2026 | NCT07412756 | A Study of Brenipatide in Adult Participants With Major Depressive Disorder | Eli Lilly and Company | Phase 3 | Recruiting | Depressive Disorder, Major | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07412756) |
| December 12, 2025 | NCT07280065 | REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool | Senseye, Inc. | Phase 3 | Recruiting | PTSD - Post Traumatic Stress Disorder | 1,900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07280065) |
| December 3, 2025 | NCT07262008 | Sustained Mood Improvement With Laughing Gas Exposure | Women's College Hospital | Phase 3 | Not yet recruiting | Major Depressive Disorder, Treatment Resistant Depression | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07262008) |
| November 12, 2025 | NCT07227454 | A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder | Janssen Research & Development, LLC | Phase 3 | Recruiting | Depressive Disorder, Major | 258 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07227454) |
| November 10, 2025 | NCT07226232 | Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression | VA Office of Research and Development | Phase 3 | Recruiting | Major Depression | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07226232) |
| October 2, 2025 | NCT07204314 | A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder | Takeda | Phase 3 | Recruiting | Major Depressive Disorder | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07204314) |
| September 29, 2025 | NCT07196501 | A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Neurocrine Biosciences | Phase 3 | Recruiting | Major Depressive Disorder | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07196501) |
| September 4, 2025 | NCT07153406 | Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Phase 3 | Not yet recruiting | Depressive Disorder | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07153406) |
| August 13, 2025 | NCT07120880 | Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia | Assistance Publique - Hôpitaux de Paris | Phase 3 | Recruiting | Major Depressive Disorder (MDD) With Insomnia | 184 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07120880) |
| July 28, 2025 | NCT07088380 | Ketamine Augmentation of ECT in Treatment-Resistant Depression | Università Vita-Salute San Raffaele | Phase 3 | Recruiting | Major Depressive Disorder, Treatment Resistant Depression | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07088380) |
| May 11, 2025 | NCT06966401 | Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive... | Neurocrine Biosciences | Phase 3 | Recruiting | Major Depressive Disorder | 850 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06966401) |
| May 8, 2025 | NCT06963021 | NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major... | Neurocrine Biosciences | Phase 3 | Recruiting | Major Depressive Disorder | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06963021) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Neurocrine Biosciences](https://specstream.ai/data/clinical-trials/company/neurocrine-biosciences) | 5 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 4 |
| [Intra-Cellular Therapies, Inc.](https://specstream.ai/data/clinical-trials/company/intra-cellular-therapies-inc) | 2 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 2 |
| Chengdu Kanghong Pharmaceutical Group Co., Ltd. | 2 |
| [Bukwang Pharmaceutical](https://specstream.ai/data/clinical-trials/company/bukwang-pharmaceutical) | 1 |
| [Vanda Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/vanda-pharmaceuticals) | 1 |
| Cybin IRL Limited | 1 |
| [Axsome Therapeutics, Inc.](https://specstream.ai/data/clinical-trials/company/axsome-therapeutics-inc) | 1 |
| All India Institute of Medical Sciences, Bhubaneswar | 1 |
| Weill Medical College of Cornell University | 1 |
| Federal University of São Paulo | 1 |
| Ain Shams University | 1 |
| Senseye, Inc. | 1 |
| Women's College Hospital | 1 |
| Cardenal Herrera University | 1 |
| Khyber Medical University Peshawar | 1 |
| Università Vita-Salute San Raffaele | 1 |
| [Takeda](https://specstream.ai/data/clinical-trials/company/takeda) | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Sunnybrook Health Sciences Centre | 1 |
| Tanta University | 1 |
| VA Office of Research and Development | 1 |
| Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 1 |
| [CSPC Ouyi Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/cspc-ouyi-pharmaceutical-co-ltd) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 21 |
| Spain | 10 |
| Canada | 9 |
| Poland | 7 |
| Taiwan | 7 |
| Bulgaria | 6 |
| Australia | 6 |
| United Kingdom | 6 |
| Italy | 6 |
| Germany | 5 |
| Brazil | 5 |
| China | 5 |
| Czechia | 4 |
| Greece | 4 |
| Romania | 4 |
| Serbia | 4 |
| South Korea | 4 |
| Japan | 4 |
| Hungary | 3 |
| Lithuania | 3 |
| Slovakia | 3 |
| Mexico | 3 |
| Argentina | 2 |
| Belgium | 2 |
| Estonia | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Software development companies in the United States](https://specstream.ai/data/businesses/software-development-companies/united-states)
- [Awning suppliers in the United States](https://specstream.ai/data/businesses/awning-suppliers/united-states)
- [Disability law firms in the United States](https://specstream.ai/data/businesses/disability-law-firms/united-states)
- [Inspection companies in the United States](https://specstream.ai/data/businesses/inspection-companies/united-states)
- [Poke restaurants in the United States](https://specstream.ai/data/businesses/poke-restaurants/united-states)
- [Vegan restaurants in the United States](https://specstream.ai/data/businesses/vegan-restaurants/united-states)
